PTEN Loss Accelerates \(Kras^{G12D}\)-Induced Pancreatic Cancer Development

Reginald Hill\(^1\), Joseph Hargan Calvopina\(^1\), Christine Kim\(^1\), Ying Wang\(^1\), David W. Dawson\(^2,3\), Timothy R. Donahue\(^1,3,4,5\), Sarah Drn\(^2,3,4\), and Hong Wu\(^1,3,4,6\)

Abstract

\(KRAS\) mutations are found in \(~90\%\) of human pancreatic ductal adenocarcinomas (PDAC). However, mice genetically engineered to express \(Kras^{G12D}\) from its endogenous locus develop PDACs only after a prolonged latency, indicating that other genetic events or pathway alterations are necessary for PDAC progression. The PTEN-controlled phosphatidylinositol 3-kinase (PI3K)/AKT signaling axis is dysregulated in later stages of PDAC. To better elucidate the role of PTEN/PI3K/AKT signaling in \(Kras^{G12D}\)–induced PDAC development, we crossed \(Pten\) conditional knockout mice (\(Pten^{lox/lox}\)) to mice with conditional activation of \(Kras^{G12D}\). The resulting compound heterozygous mutant mice showed significantly accelerated development of acinar-to-ductal metaplasia (ADM), malignant pancreatic intraepithelial neoplasia (mPanIN), and PDAC within a year. Moreover, all mice with \(Kras^{G12D}\) activation and \(Pten\) homozygous deletion succumbed to cancer by 3 weeks of age. Our data support a dosage-dependent role for PTEN, and the resulting dysregulation of the PI3K/AKT signaling axis, in both PDAC initiation and progression, and shed additional light on the signaling mechanisms that lead to the development of ADM and subsequent mPanIN and pancreatic cancer. Cancer Res; 70(18); 7114–24. ©2010 AACR.

Introduction

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest of all cancers with a 5-year survival rate of \(<5\%\). Genetically engineered mouse models that recapitulate the human disease (1) have become essential tools in the dissection of the cellular and molecular pathogenesis of PDAC and the preclinical assessment of novel biomarkers and therapeutics. The most studied model to date has been the \(Pdx1\)-Cre–mediated expression of a knock-in mutant allele of \(Kras\) with a glycine to aspartic acid substitution (\(Pdx1\)-Cre\(Kras^{G12D/G12D}\)) from its endogenous locus. These mice slowly develop premalignant pancreatic intraepithelial neoplasias (mPanIN) with prolonged latencies and incomplete penetrance for the development of PDAC (2). However, PDAC developed far more rapidly when \(Pdx1\)-Cre\(Kras^{G12D/G12D}\) mice were crossed with mice deficient in one of the genes commonly associated with PDAC, such as \(Ink4a/Arf\) (3), transforming growth factor-\(\beta\) (TGF-\(\beta\)) receptor type 2 (Tgfr2; ref. 4), and Smad4 (5), or carrying a mutation in \(p53\) (6), although these molecular alterations alone do not lead to the development of pancreatic cancer in the absence of oncogenic \(Kras\). These data indicate that additional genetic events beyond \(Kras\) mutation are responsible for pancreatic cancer progression. To date, the function of phosphatase and tensin homologue (PTEN) tumor suppressor, which is mutated in PDAC far less frequently (7, 8), has yet to be examined in the context of mutant \(Kras^{G12D}\) activation. In this study, we examined the effects of concomitant \(Pten\) deletion and \(Kras^{G12D}\) activation and observed an accelerated and accentuated phenotype of acinar-to-ductal metaplasia (ADM), leading to mPanIN and malignant progression. Our findings indicate that concurrent dysregulation of the PTEN/phosphatidylinositol 3-kinase (PI3K)/AKT and RAS/RAF/mitogen-activated protein kinase (MAPK) pathways acts synergistically to promote pancreatic cancer initiation and progression. This model provides us with a means to explore the role of PTEN and the PI3K-AKT signaling axis in pancreatic tumor development and treatment.

Materials and Methods

Mouse strains

To generate \(Pdx1\)-Cre\(Pten^{lox/lox}\);\(Kras^{G12D/G12D}\) and \(Pdx1\)-Cre\(Pten^{lox/lox}\);\(Kras^{G12D/G12D}\) mice, we backcrossed the \(Kras^{G12D/G12D}\) line (on a C57 background; ref. 2) to the \(Pten^{lox/lox}\) line (on a 129/ BALB/c background) twice to generate \(Kras^{G12D/G12D}\);\(Pten^{lox/lox}\)
mice. We then crossed \(\text{Kras}^{\text{G12D}}/\text{Pten}^{\text{floxed}}\) mice to \(\text{Pdx1-Cre}^+\); \(\text{Pten}^{\text{floxed/+}}\) mice we had previously generated (9) to produce experimental animals on a mixed C57/BL/6,129/BALB/c background. All studies were performed under the regulation of the Division of Laboratory Animal Medicine at the University of California at Los Angeles (UCLA). \(\text{Kras}^{\text{G12D}}\) primers, designed to recognize the \(\text{Kras}^{\text{G12D}}\) mutant allele (10), and \(\text{Pten}\) primers, which detect the \(\text{Pten}\) floxed allele (11), were used to confirm the genotypes of mice from the breeding crosses.

**Histology and immunohistochemistry**

Immunohistochemical analysis was performed on formalin-fixed, paraffin-embedded tissue. Antigen retrieval was performed by heating the slides at 95°C in citrate buffer (pH 6.0) for 15 minutes before staining. The following primary antibodies were used: rabbit anti–phospho-AKT (Ser\(^{473}\); 1:50; Cell Signaling), guinea pig anti-\(\beta\)-catenin (1:5,000; a gift from Chris Wright, Vanderbilt University, Nashville, TN), rabbit anti–smooth muscle actin (SMA) (1:1,000; Sigma), rabbit anti-Ki67 (1:1,000; Vector Labs), rabbit anti-amylose (1:500; Sigma), mouse anti–cytokeratin 19 (CK19; 1:100; Abcam), mouse anti–pan-cytokeratin (1:500; Abcam), mouse anti–phospho-S6 (Ser\(^{240/244}\); 1:100; Cell Signaling), rat anti-mouse/human CD44 (1:50; ebiosciences), mouse anti–smooth muscle actin (SMA\(\alpha\)) (1:1,000; Sigma), rabbit anti–platelet-derived growth factor receptor \(\beta\) (PDGFR\(\beta\); 1:100; Cell Signaling), and rabbit anti–cyclin D1 (1:25; Cell Signaling). Biotinylated Dolichos biflorus lectin (Vector Labs) was used at 1:250 in HEPES/NaCl.

The collection of all human tumor samples used for this study was approved by the UCLA Institutional Review Board. The UCLA Pathology databases were used to identify patients with PDAC. Slides from the selected cases were reviewed. Anonymously labeled sections for immunohistochemistry studies, as detailed above, were prepared by the UCLA Department of Pathology Translational Pathology Laboratory Core facility. Additionally, an H&E-stained slide was made from each block to confirm the diagnosis.

**Proliferation index and statistical evaluation**

The proliferation index for ADMs and mPanINs was determined by averaging the percentage of Ki67-positive cells per field for 10 fields at \(\times 400\) magnification (n = 4). Each field selected contained only ADMs or only mPanINs. The percentage of Ki67-positive cells was determined as the number of Ki67-positive cells per field (excluding positive cells in the stroma or untransformed acinar cells)/total cells per field (excluding cells in the stroma). Differences between mice in each cohort were evaluated by Student’s t test. \(P < 0.05\) was considered of statistical significance.

**Histopathologic scoring of murine pancreatic lesions**

H&E-stained sections were reviewed by R.H. and H.W. and two pathologists with extensive experience in murine and human pancreas pathology (D.W.D. and S.D.). Histopathologic lesions in mouse pancreata were scored in blinded fashion using serial step sections (20 \(\mu\)m apart, four sections per mouse) and consensus criteria established at the 2004 Penn Workshop (12).

**Laser capture microdissection and loss of heterozygosity analysis**

Laser capture microdissection (LCM) of H&E-stained pancreatic sections was performed using an Arcturus PixCell Ile LCM system. Approximately 50 cells from mPanINs or PDACs in \(\text{Pdx1-Cre}^+\); \(\text{Kras}^{\text{G12D}}/\text{Pten}^{\text{floxed/+}}\) were collected on CapSure HS LCM caps (Molecular Devices). DNA was extracted by 16-hour incubation (55°C) in the ExiSure sample extraction devices (Molecular Devices) with lysis buffer [10 mmol/L Tris-HCl (pH 8.0), 1% Tween 20, 100 \(\mu\)g proteinase K]. Following incubation, proteinase K was inactivated by incubation at 99°C for 10 minutes, and 1-\(\mu\)L aliquots of DNA were used for PCR analysis. PCR was performed for detection of wild-type (WT), floxed, and recombinant alleles of \(\text{Pten}\) using previously described primers (11).

**Results**

**PTEN dosage controls pancreatic cancer progression in the \(\text{Pdx1-Cre}^+\); \(\text{Kras}^{\text{G12D}}/\text{Pten}^{\text{floxed/+}}\) mouse model**

The prolonged latencies and incomplete penetrance for the development of PDAC observed in the \(\text{Pdx1-Cre}^+\); \(\text{Kras}^{\text{G12D}}/\text{Pten}^{\text{floxed/+}}\) mouse model prompted us to determine whether alteration of the PTEN/PI3K pathway could promote accelerated PDAC initiation and progression. For this, we crossed the \(\text{Pdx1-Cre}^+\); \(\text{Kras}^{\text{G12D}}/\text{Pten}^{\text{floxed/+}}\) model (2) with the \(\text{Pten}\) conditional knockout line we had previously generated (9). We found that \(\text{Pten}\) haploinsufficiency significantly shortened the life span of \(\text{Pdx1-Cre}^+\); \(\text{Kras}^{\text{G12D}}/\text{Pten}^{\text{floxed/+}}\) mice to a median survival of \(3.5\) months (green line in Fig. 1A; \(\text{Pdx1-Cre}^+\); \(\text{Kras}^{\text{G12D}}/\text{Pten}^{\text{floxed/+}}\); \(n = 45\)). Most \(\text{Pdx1-Cre}^+\); \(\text{Kras}^{\text{G12D}}/\text{Pten}^{\text{floxed/+}}\) mice exhibited abdominal distension due to a combination of ascites fluid and pancreatic enlargement, at which time the animals were sacrificed. Nearly 100% of the \(\text{Pdx1-Cre}^+\); \(\text{Kras}^{\text{G12D}}/\text{Pten}^{\text{floxed/+}}\) mouse exhibited normal growth without any signs of abdominal distension. PDACs in \(\text{Pdx1-Cre}^+\); \(\text{Kras}^{\text{G12D}}/\text{Pten}^{\text{floxed/+}}\) mouse exhibited early signs of cancerous behavior by 12 months compared with 90% survival of the \(\text{Pdx1-Cre}^+\); \(\text{Kras}^{\text{G12D}}/\text{Pten}^{\text{floxed/+}}\) model (blue line in Fig. 1A; \(n = 25\)). We examined sections from the pancreata of each transgenic model to score the presence of different grades of mPanIN or PDAC lesions, which were defined by the consensus criteria of the pancreatic mouse modeling community (13). Histologic examination showed evidence of accelerated PDAC development in \(\text{Pdx1-Cre}^+\); \(\text{Kras}^{\text{G12D}}/\text{Pten}^{\text{floxed/+}}\) mice compared with \(\text{Pdx1-Cre}^+\); \(\text{Kras}^{\text{G12D}}/\text{Pten}^{\text{floxed/+}}\) littermate controls. Whereas \(\text{Pdx1-Cre}^+\); \(\text{Kras}^{\text{G12D}}/\text{Pten}^{\text{floxed/+}}\) mice exhibited limited early-stage mPanIN lesions within an otherwise normal pancreas parenchyma at 3 months, \(\text{Pdx1-Cre}^+\); \(\text{Kras}^{\text{G12D}}/\text{Pten}^{\text{floxed/+}}\) mice showed an almost complete loss of normal gland architecture and were involved by invasive ductal tumors histologically similar to human PDACs [Fig. 1A (right) and B (bottom)]. Invasive cancers were defined as the presence of malignant ductal epithelial cells, identifiable by CK19 staining, which had penetrated through the basement membrane into the surrounding SMA-positive stroma (Fig. 1B). Twenty-one of 25 \(\text{Pdx1-Cre}^+\); \(\text{Kras}^{\text{G12D}}/\text{Pten}^{\text{floxed/+}}\) mice exhibited cancerous behavior by 12 months.
mice alive past 2 months of age developed well-to-moderately differentiated invasive ductal cancers. The spleen, liver, and lungs of tumor-bearing mice were examined, with only rare microscopic metastasis to the lungs noted ($n = 2$; data not shown). The metastatic lung lesions histologically resembled the primary pancreatic tumor. The infrequent rate of metastasis indicates that the mice rapidly succumb to their primary cancers before...
the time needed to develop metastatic lesions and/or that other genetic events are necessary for metastasis.

Mice with KrasG12D activation and homozygous Pten deletion had an even earlier onset of lethal PDAC. Pdx1-Cre; KrasG12D/Ptenlox/lox mice were moribund and either naturally succumbed or had to be euthanized before weaning (red line in Fig. 1A; n = 26). Histopathologic examination of the pancreata of the Pdx1-Cre; KrasG12D/Ptenlox/lox mice from postnatal days 1 to 17 (P1–P17) showed pancreatic enlargement (Supplementary Fig. S1A, left) and severe exocrine pancreatic atrophy and edema. In addition, the presence of mPanINs, metaplasias, ducto-insular complexes (endocrine cells that contain aberrantly proliferating ductules; ref. 13), and cancer formation was observed (Supplementary Fig. S1A, right). Consistent with phenotypes observed in human PDAC (Fig. 1B; refs. 15, 16). Using double immunofluorescence analysis, we observed that the majority of tumor cells in Pdx1-Cre; KrasG12D/Ptenlox/lox pancreata are CK19 and DBA lectin (14), as well as their invasive behavior (12). Similar to human pancreatic cancers, the PDAC lesions in Pdx1-Cre; KrasG12D/Ptenlox/lox pancreata were positive for DBA and PDX1, a transcription factor associated with early pancreatic development and known to be upregulated in human PDAC (Fig. 1B; refs. 15, 16). Having established that Pten haploinsufficiency led to earlier development of mPanIN lesions, we next examined if PDAC development was accelerated as well. At 3 months of age, 8 of 12 Pdx1-Cre; KrasG12D/Ptenlox/lox mice showed the development of PDACs (Fig. 2B, black columns), whereas Pdx1-Cre; Ptenloxp/ or Pdx1-Cre; KrasG12D/Ptenlox/lox mice of the same age (n = 5 and 7, respectively) show no evidence of PDAC development (Fig. 2B, white or gray columns, respectively). Ultimately, all Pdx1-Cre; KrasG12D/Ptenlox/lox mice that we examined at the 6-month time point (n = 6) showed evidence of PDAC (Fig. 2B, black columns) compared with 2 of 11 Pdx1-Cre; KrasG12D/Ptenlox/lox mice (Fig. 2B, gray columns). Therefore, the Pten/PI3K/akt and RAS/RAF/MAPK pathways synergize at both initiation and progression steps of PDAC development.

We next determined if the synergy between the Pten/PI3K/akt and RAS/RAF/MAPK pathways in PDAC development requires complete loss of Pten function or loss of heterozygosity (LOH). For this, we first evaluated the status of phosphorylated p44/42 MAPK (P-ERK), Akt (P-AKT), and S6 (P-S6), surrogate markers for dysregulated RAS/RAF/MAPK and Pten/PI3K/akt pathways, respectively, in the mPanINs and PDACs of Pdx1-Cre; KrasG12D/Ptenlox/lox and Pdx1-Cre; KrasG12D/Ptenlox/lox mice. Immunohistochemistry showed positive staining of P-ERK, but not P-AKT or P-S6, in the stage-matched mPanIN lesions of both Pdx1-Cre; KrasG12D/Ptenlox/lox and Pdx1-Cre; KrasG12D/Ptenlox/lox mice (Fig. 2A, right), indicating that it was unlikely that LOH had happened at this stage in lesion development. On the other hand, PDACs in 6-month-old Pdx1-Cre; KrasG12D/Ptenlox/lox mice showed positive staining for P-ERK, P-AKT, and P-S6, strongly indicating that Pten LOH may have occurred in these lesions (Fig. 2B, right).

To confirm if Pten LOH indeed happened during PDAC progression, we used LCM to separate PDAC lesions from adjacent mPanINs in Pdx1-Cre; KrasG12D/Ptenlox/lox mice (n = 5; Supplementary Fig. S2B, left) and performed PCR analysis using DNA isolated from the microdissected tissues. As shown in Supplementary Fig. S2B (right), all of the PDAC lesions showed the presence of a band corresponding to the Cre-mediated Pten deletion product, whereas four of five showed absence of the WT Pten allele, indicating that Pten LOH had occurred in these samples (the WT band in sample 3 could have come from stromal cell contamination). In contrast, all adjacent mPanIN lesions showed the presence of the WT allele (Supplementary Fig. S2B, right, bottom, outlined in red). Taken together, these findings suggest that whereas Pten LOH contributes to PDAC development in the Pdx1-Cre; KrasG12D/Ptenlox/lox model, Pten haploinsufficiency, as observed in other systems (17), is sufficient to cause accelerated mPanIN initiation.
ADM development precedes mPanIN formation in Pdx1-Cre;Kras\textsuperscript{G12D};Pten\textsuperscript{lox/+} mice

When we examined the pathology of the Pdx1-Cre\textsuperscript{+};Kras\textsuperscript{G12D};Pten\textsuperscript{lox/lox} mice between 1 and 3 months of age, we observed, in addition to traditional mPanIN lesions, a large number of ADMs (Fig. 3A, top left, white arrow), similar to the metaplasias (12) we had observed in the Pdx1-Cre;Pten\textsuperscript{lox/+} model (9). These ADMs were concentrated in the “transition zone” between morphologically normal pancreatic structures and mPanIN and PDAC lesions and could be easily identified on H&E-stained sections, where ductal, tubular structures, often with mucinous cytoplasm, emerged from acinar cells. These structures can be numerous, replacing the normal acinar parenchyma, and are thought to possibly arise from either acinar (18) or centroacinar cells (9). H&E-stained sections from resected human tumors revealed similar pathology in areas adjacent to PDAC (Fig. 3A, white arrow). Double immunofluorescence confirmed that these lesions in fact contained duct-like cells (pan-cytokeratin labeled; green) within acinar structures (amylase; red; Fig. 3A, white arrow). ADMs were also observed in the Pdx1-Cre;Kras\textsuperscript{G12D/+} mice but were not observed in WT controls (Fig. 3B).
To decipher the relationship between ADM and mPanINs, we first investigated the chronological appearance of the two lesions. Although no mPanIN lesions were detected in the pancreata of *Pdx1-Cre*⁺⁺*KrasG12D/+* and *Pdx1-Cre*⁺⁺*Ptenlox/⁻* mice at 1 month of age, one of five *Pdx1-Cre*⁺⁺*KrasG12D/+* mice and three of six *Pdx1-Cre*⁺⁺*KrasG12D/+*⁺⁺*Ptenlox/⁻* mice showed ADM alone, and another two of six *Pdx1-Cre*⁺⁺*KrasG12D/+*⁺⁺*Ptenlox/⁻* mice showed both metaplasias and mPanIN lesions (Fig. 3B). Interestingly, none of the animals developed mPanIN lesions only, suggesting that (a) metaplasias are the earliest pathologic lesions identified in the *Pdx1-Cre*⁺⁺*KrasG12D/+* and *Pdx1-Cre*⁺⁺*KrasG12D/+*⁺⁺*Ptenlox/⁻* mice, (b) KRAS and PTEN/PI3K pathways collaborate to promote metaplasia development, and (c) ADMs likely serve as the precursors of mPanINs or parallel with mPanIN in pancreatic cancer development.

ADM may serve as the precursor of PDAC in *Pdx1-Cre*⁺⁺*KrasG12D/+*⁺⁺*Ptenlox/⁻* mouse model and human cancers

To investigate the functional significance of metaplasias in pancreatic cancer development, we quantified the proliferation of metaplasia and mPanIN lesions on stage-matched *Pdx1-Cre*⁺⁺*KrasG12D/+* and *Pdx1-Cre*⁺⁺*KrasG12D/+*⁺⁺*Ptenlox/⁻* mice (see Materials and Methods; Fig. 4; n = 4). The proliferation index of metaplasia lesions was significantly higher than that of the mPanIN lesions in both the *Pdx1-Cre*⁺⁺*KrasG12D/+* (7.4% versus 2.4%) and *Pdx1-Cre*⁺⁺*KrasG12D/+*⁺⁺*Ptenlox/⁻* cohorts (11.4% versus 6.2%; Fig. 4). Moreover, there was a significant increase in the proliferation rates of both types of lesions in *Pdx1-Cre*⁺⁺*KrasG12D/+*⁺⁺*Ptenlox/⁻* mice compared with *Pdx1-Cre*⁺⁺*KrasG12D/+* mice. This shows not only that ADMs precede the development of mPanINs but also that *Pten* haploinsufficiency makes the already more rapidly dividing ADMs even more proliferative, which could contribute to accelerated disease initiation and progression.

**Increase in CD44-positive cells in murine and human metaplastic lesions**

CD44 is a cell surface glycoprotein known to be upregulated in human PDACs (19) and has been used as a marker to identify a stem-like subpopulation in the pancreas (20). CD44-positive cells were present in the early ADMs in the *Pdx1-Cre*⁺⁺*KrasG12D/+*⁺⁺*Ptenlox/⁻* model as well as in human samples (Fig. 5A, top row; Supplementary Fig. S3B) but almost absent in the nearby mPanINs (Fig. 5A, bottom row) or in normal acinar and ductal cells (Supplementary Fig. S3A). Interestingly, we observed high CD44 expression in the invasive PDAC lesions in *Pdx1-Cre*⁺⁺*KrasG12D/+*⁺⁺*Ptenlox/⁻* mice (Fig. 5B, top row), which matches the CD44 staining pattern observed in human PDAC samples (Fig. 5B, bottom row). The level of CD44 staining was much less intense in the PDAC lesions in *Pdx1-Cre*⁺⁺*KrasG12D/+*⁺⁺*Ptenlox/⁻* mice (Supplementary Fig. S3A). Taken together, these data suggest that PTEN/P3K and KRAS pathways collaborate in accelerating ADM development and in turn promote CD44-positive PDAC formation.
Discussion

PTEN and pancreatic cancer development

Even with improvements in surgical techniques, the overall survival rate for patients with PDAC remains dismal. There is still much to be learned about the origin and development of PDAC, but unfortunately, most of our knowledge about this disease comes from biopsies of patients with late-stage tumors, making it difficult to determine which cell types, and more importantly which molecular changes, are important for disease onset and progression. Animal models that faithfully recapitulate both the histology and molecular profile of the human disease have been an indispensable tool, which has allowed us to dissect out the role various genetic events play in the initiation and progression of PDAC. Mutations in KRAS resulting in its constitutive activation occur in >90% of PDACs (21). However, mice expressing Kras<sup>G12D</sup> from its endogenous locus progress to invasive cancers only after a prolonged latency (2) unless coupled with other genetic alterations commonly found in human PDAC (21). Previous studies using the Kras<sup>G12D</sup> mouse model, where median survival is 15 months (2), have shown that homozygous deletion of both the p16<sup>Ink4A</sup> and p19<sup>Arf</sup> loci decreased survival to 8 weeks (3). Likewise, Kras<sup>G12D</sup> mice with either p53, type II TGF-β receptor gene (Tgfbr2), or Smad4 inactivation show accelerated development of PDACs with median survival times of 5, 4, or 2 months, respectively (4–6). Our study shows that loss of PTEN function causes accelerated cancer development and decreased survival in the Kras<sup>G12D</sup> mouse model to either 3.5 months in the case of heterozygous Pten or 3 weeks with homozygous Pten deletion (Figs. 1 and 2). Although point mutations or LOH in PTEN rarely occur in human PDAC (7, 8), there is evidence to support that loss of PTEN function or alteration of PTEN-controlled signaling pathways can occur through alternative mechanisms, including promoter methylation (22), increased expression of AKT2 (23), or reduction of mRNA levels (24). In addition, the expression of several signaling pathways linked to PDAC development, including RAS (25), TGF-β (26, 27), and insulin-like growth factor-1 (28), has been shown to downregulate the expression of PTEN or inactivate the catalytic activity of PTEN, leading to reduced apoptosis (25), increased cell motility (26, 27), and increased cell proliferation and invasion (28) in pancreatic cancer cells. Therefore, although PTEN itself is not mutated frequently in the human disease, PTEN and PTEN-controlled pathways are being modulated in ways that are critical for disease development.

Pdx1-Cre<sup>+</sup>;Kras<sup>G12D</sup>+/−;Pten<sup>lox/lox</sup> mice recapitulate human PDAC

Histologic and immunohistochemical analysis verified that the cancers in Pdx1-Cre<sup>+</sup>;Kras<sup>G12D</sup>+/−;Pten<sup>lox/lox</sup> mice recapitulated the pathologic features of human PDACs (Fig. 1B). Despite their rapid tumor onset, which is similar in latency to mice with p16<sup>Ink4A</sup> and p19<sup>Arf</sup> deletion, Pdx1-Cre<sup>+</sup>;Kras<sup>G12D</sup>+/−;Pten<sup>lox/lox</sup> mice do not show the development of a large percentage of sarcomatoid tumors, a tumor type that makes up only a small portion of the human disease but is prevalent in the Pdx1-Cre<sup>+</sup>;Kras<sup>G12D</sup>+/−;Ink4a/Arf<sup>lox/lox</sup> model (3). In this respect, the Pdx1-Cre<sup>+</sup>;Kras<sup>G12D</sup>+/−;Pten<sup>lox/lox</sup> mice are similar to...
the *Ptf1a-Cre*;*Kras* 


generated mice that developed well-differentiated ductal adenocarcinomas with no evidence of sarcomatoid features (4). The drastic acceleration of PDAC development and early lethality seen in these two models may explain why metastases are only seen in a few cases when animals live well beyond the median survival age. The two metastases found in our *Pdx1-Cre*;*Kras* 


can be explained by the limited number of metastases observed in the *Pdx1-Cre*;*Kras* 


cancer models where metastases are discovered in mice at 20 and 24 weeks of age. This limited number of metastases observed in the *Pdx1-Cre*;*Kras* 


cancer model makes it unlikely that the mice succumb to their primary cancers before the time needed to develop metastatic lesions and/or that other genetic events found in late-stage tumors (such as *p16Ink4A*, *p19Arf*, *p53*, or *Smad4* deletion; ref. 21) are necessary for metastasis development.

**Pdx1-Cre*;*Kras* 


cancer mice drive tumor progression through non–cell-autonomous mechanisms?**

The *Pdx1-Cre*;*Kras* 


cancer model provides a valuable resource for studying the alterations that are required to push an invasive cancer to one with metastatic potential. Even without evidence of prominent metastases, invasive tumors in *Pdx1-Cre*;*Kras* 


cancer mice show significant...
changes not only in the epithelial cell compartment but also in the surrounding desmoplastic stroma, again recapitulating the nature of the human disease. Pdx1-Cre<sup>+</sup>;Kras<sup>G12D</sup>/++;Pt<sup>lox/lox</sup> mice showed a significant stromal component (as marked by SMA-positive staining) surrounding both mPanINs and PDACs (Fig. 1B). While investigating the nature of the desmoplastic stroma seen in the tumors of Pdx1-Cre<sup>+</sup>;Kras<sup>G12D</sup>/++;Pt<sup>lox/lox</sup> mice, we observed increased staining for PDGFB<sub>β</sub> in the stroma of Pdx1-Cre<sup>+</sup>;Kras<sup>G12D</sup>/++;Pt<sup>lox/lox</sup> mice compared with that of Pdx1-Cre<sup>+</sup>;Kras<sup>G12D</sup> alone. This staining pattern matched what was observed in the human samples (Supplementary Fig. S3A), as human PDACs are characterized by induction of PDGFB<sub>β</sub> expression in the stromal compartment (29). The presence of cells positive for PDGFB<sub>β</sub> has been found to aid tumor angiogenesis through pericyte recruitment (30), and it is believed that targeting vascular endothelial growth factor receptor (VEGFR) and PDGFB<sub>β</sub> may be capable of preventing the growth of some types of pancreatic cancers (31). This strongly suggests that combined alteration of the PTEN/PI3K and KRAS pathways in the epithelial cells can elicit a protumorigenic response from the surrounding microenvironment through non–cell-autonomous mechanisms.

**Kras<sup>G12D</sup> activation and Pten haploinsufficiency are sufficient for accelerated lesion development**

Our results show that Pten LOH corresponded only with PDAC development in this mouse model (Supplementary Fig. S2B). This raises the question of what is driving earlier mPanIN or ADM development in the Pdx1-Cre<sup>+</sup>;Kras<sup>G12D</sup>/++;Pt<sup>lox/lox</sup> mice because we cannot detect Pten LOH in either of these precursor lesions (Supplementary Figs. S2B and S3C). This earlier onset could be brought about by the increased cell proliferation that results from the synergy between the KRAS and PI3K/AKT pathway alterations. Both ADMs and mPanINs in Pdx1-Cre<sup>+</sup>;Kras<sup>G12D</sup>/++;Pt<sup>lox/lox</sup> mice showed an increased rate of proliferation compared with their Pdx1-Cre<sup>+</sup>;Kras<sup>G12D</sup>/++ littermates (Fig. 4). In addition, these early ADMs and PDACs in Pdx1-Cre<sup>+</sup>;Kras<sup>G12D</sup>/++;Pt<sup>lox/lox</sup> mice showed intense staining of cyclin D1 (Supplementary Fig. S3A), which has been shown to be regulated by PTEN levels (32, 33). The selective pressure to acquire additional genetic alteration brought about by this accelerated proliferation is likely what contributes to the Pten LOH seen in the PDACs in this model.

Moreover, PTEN is capable of regulating gene expression via hypoxia-inducible factor-1 (HIF-1; ref. 34). A study that identified genes regulated by Pten haploinsufficiency identified several known HIF-1–regulated genes, including VEGF (35). Emerging evidence has linked loss of PTEN function with increased PDGFB<sub>β</sub> expression in malignant tumors (36), so it is possible that in Pdx1-Cre<sup>+</sup>;Kras<sup>G12D</sup>/++;Pt<sup>lox/lox</sup> mice, Pten haploinsufficiency acts to induce HIF-1, which in turn could induce VEGF and PDGFB<sub>β</sub> expression. Thus, the Pten pathways could play a critical role in controlling the angiogenesis of invasive PDACs. The Pdx1-Cre<sup>+</sup>;Kras<sup>G12D</sup>/++;Pt<sup>lox/lox</sup> mice will provide a good resource to study how angiogenesis affects tumor development and whether targeting tumors with compounds such as sunitinib (alone or in combination with other drugs) will yield therapeutic results.

**Acinar cell of origin?**

Recent work has shown that Kras<sup>G12D</sup> mice with alterations in SMAD4 (5) and TGF-β signaling (4) have an increase in ADM formation accompanying tumor acceleration. Likewise, expression of the Kras<sup>G12D</sup> oncogene in the acinar/centroacinar lineage results in ADMs, preceding the development of mPanINs and invasive PDAC (18). In addition, although mice with Kras<sup>G12D</sup> activation and NOTCH gain of function did not progress to PDAC, a significant acceleration of ADM reprogramming leading to mPanIN formation was observed (37). Our analysis indicates that Pten haploinsufficiency in Kras<sup>G12D</sup> mice is also sufficient to accelerate the development of ADM lesions (Figs. 2 and 3), adding to the growing lines of evidence (18, 37, 38) that show that these ADMs are the earliest precursor lesions seen in the Kras<sup>G12D</sup> mouse models. The development of metaplasias precedes mPanINs in both the Pdx1-Cre<sup>+</sup>;Kras<sup>G12D</sup>/++ and
Pdx1-Cre;KrasG12D/+;Ptenlox/lox mice (Fig. 3B), suggesting that although PTEN dosage plays a critical role in promoting metaplasia development, ADMs are likely the actual precursor lesions that give rise to the neoplastic ducts seen in PDAC regardless of PTEN function. Our hypothesis, which will require vigorous experimental testing using more sophisticated methodologies such as lineage tracing, is that ADMs, independent of mPanIN development, are capable of giving rise to PDAC. We have also observed mPanIN/ADM hybrid lesions, as reported by other studies, which have linked metaplasia with mPanIN development (18, 38). Taken together, these observations indicate that some lesions traditionally identified as mPanINs most likely developed from the preexisting metaplasias. The fact that we see more proliferation in ADMs than mPanINs (Fig. 4) could indicate that mPanINs may be a more quiescent, intermediate state between ADM and PDAC (Fig. 6). Alternatively, it is possible, as others have suggested (37), that mPanINs (Fig. 4) could indicate that mPanINs may be a more quiescent state for highly proliferative precursor lesions that would have otherwise immediately progressed to PDAC. Given their earlier appearance and hyperproliferative features (Fig. 4), it is possible that most ADMs generated in this model due to Pten haploinsufficiency could develop directly into PDACs, bypassing the mPanIN stage. Interestingly, no evidence of P-AKT was detectable by immunohistochemistry in early metaplasias (Supplementary Fig. S3c). Likewise, our data showed that similar to mPanINs, ADMs showed no evidence of Pten LOH (data not shown). Further studies using isolated lesion populations will have to be performed to uncover the exact mechanism through which Pten haploinsufficiency leads to earlier ADM.

Regulation of cancer stem cells?

In our study, we also observed that the ADMs contained more CD44-positive cells than mPanINs and PanINs (Fig. 5A). Expression of CD44 has recently been used as a marker for isolating cancer stem cells in many tumors (39, 40), and its expression has been linked to poor prognosis and gemcitabine resistance in pancreatic cancer (41). Moreover, metaplastic, highly aggressive, chemoresistant tumors in the breast (42) and breast (42) have been shown to have an increase of P38/akt pathway components (43). It will be interesting to test whether (a) some stroma contains stem cell–like properties, (b) PTEN loss leads to the enrichment of tumor-initiating/stem cells, and (c) CD44 upregulation on lesion initiation may aid tumor survival through PI3K/AKT-dependent pathways.

Previous work with mice with only Pten deficiency in the pancreas (9) showed that loss of PTEN function in Pdx1-Cre;KrasG12D/+;Ptenlox/lox mice led to centroacinar cell expansion, which produced metaplasias similar to what is seen in Pdx1-Cre;KrasG12D/+;Ptenlox/lox mice. However, although both models exhibit metaplasia, the tumors in Pdx1-Cre;Ptenlox/lox mice are more papillary in nature, whereas Pdx1-Cre;KrasG12D/+;Ptenlox/lox tumors seem identical to Pdx1-Cre;KrasG12D/+;Ptenlox/lox mice. This could indicate that the phenotype in the Pdx1-Cre;Ptenlox/lox mice might reflect the consequence of Pten loss in the centroacinar cell compartment, whereas the phenotype in the Pdx1-Cre;KrasG12D/+;Ptenlox/lox mice mimics that of the human disease. This model provides a valuable resource for elucidating how loss of PTEN function aids tumor development and for determining whether targeting PI3K/AKT signaling is a viable therapeutic strategy.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

We thank the UCLA Tissue Procurement Core Laboratory for their technical help, Dr. Bangyan Stiles for sharing protocols, and Antreas Hindoyan for helpful discussions.

Grant Support

Damon Runyon Cancer Foundation and U.S. Department of Health and Human Services Ruth L. Kirschstein Institutional National Research Service Award T32 CA009056 (R. Hill and J.H. Calvopina), UCLA Jonsson Comprehensive Cancer Center Seed, and NIH grants U01 CA84128 and RO1 CA107166 (H. Wu).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 05/10/2010; revised 07/08/2010; accepted 07/13/2010; published OnlineFirst 08/31/2010.

References


www.aacrjournals.org Cancer Res; 70(18) September 15, 2010 7123

Published OnlineFirst August 31, 2010; DOI: 10.1158/0008-5472.CAN-10-1649


PTEN Loss Accelerates $Kras^{G12D}$-Induced Pancreatic Cancer Development

Reginald Hill, Joseph Hargan Calvopina, Christine Kim, et al.

*Cancer Res* 2010;70:7114-7124. Published OnlineFirst August 31, 2010.